Contact: +91-9711224068
  • Printed Journal
  • Indexed Journal
  • Refereed Journal
  • Peer Reviewed Journal
International Journal of Dermatology Sciences

Vol. 6, Issue 1, Part B (2024)

Comparative study between escitalopram and vortioxetine in case of premature ejaculation-50 cases

Author(s):

Md. Nazmul Haque Sarker, Samia Subreen Shila, Kismat Ara Islam and Muhammad Humayoun Kabir

Abstract:

Background: Premature ejaculation (PE) is a common sexual dysfunction affecting men worldwide. While selective serotonin reuptake inhibitors (SSRIs) like escitalopram have shown efficacy in PE treatment, there is ongoing research into alternative medications with potentially fewer side effects. This study compares the efficacy and tolerability of escitalopram with vortioxetine, a novel antidepressant with a multimodal mechanism of action, in the treatment of PE.

Methods: In this prospective, randomized, double-blind, parallel-group clinical trial, 50 adult men diagnosed with PE were randomly assigned to receive either escitalopram (10 mg daily) or vortioxetine (10 mg daily) for 12 weeks. The primary outcome measure was the change in intravaginal ejaculatory latency time (IELT). Secondary outcomes included the Premature Ejaculation Profile (PEP), International Index of Erectile Function (IIEF), Clinical Global Impression of Change (CGI-C), and adverse events.

Results: Both medications significantly increased IELT over the 12-week treatment period. The mean percentage increase in IELT from baseline to week 12 was 509% for escitalopram and 400% for vortioxetine (p = 0.03). Escitalopram showed slightly superior improvements in PEP scores for perceived control and satisfaction (p< 0.05). Both medications were well-tolerated, with similar overall adverse event profiles. However, vortioxetine showed a trend towards lower incidence of decreased libido (8% vs. 16% for escitalopram, p = 0.38).

Conclusion: Both escitalopram and vortioxetine demonstrated significant efficacy in treating PE, with escitalopram showing slightly superior results in IELT and some secondary outcomes. Vortioxetine's efficacy and potentially more favorable sexual side effect profile suggest it may be a valuable alternative treatment option for PE, particularly for patients who do not respond well to or cannot tolerate traditional SSRIs.

Pages: 87-92  |  314 Views  181 Downloads


International Journal of Dermatology Sciences
How to cite this article:
Md. Nazmul Haque Sarker, Samia Subreen Shila, Kismat Ara Islam and Muhammad Humayoun Kabir. Comparative study between escitalopram and vortioxetine in case of premature ejaculation-50 cases. Int. J.Dermatol. Sci. 2024;6(1):87-92. DOI: 10.33545/26649772.2024.v6.i1b.39
Call for book chapter